Did you miss our cBHT campaign sneak peek?
APC's open town hall meeting yesterday gave more than 120 compounders an exciting update on our campaign to save cBHT — a campaign set to launch next month.
APC's open town hall meeting yesterday gave more than 120 compounders an exciting update on our campaign to save cBHT — a campaign set to launch next month.
An occasional column in which an attorney responds to an ethical question compounders may confront. This week: kickbacks
APC CEO Scott Brunner sent a letter this week to FDA's acting director of its Office of Compounding Quality and Compliance
APC has two new resources on the issue of "constructive transfer" — i.e., transferring a controlled substance to the prescribing/treating physician or veterinarian for administration or safekeeping.
The FDA has published its concerns about compounding during the pandemic, specifically regarding two drugs: thymosin and remdesivir.
A group of five organizations, led by APC, this week filed a “friend-of-the-court” brief in support of litigation challenging FDA’s MOU with states.
Have you downloaded the new APC Compounder's Code of Ethics?
We're issuing a CALL TO ACTION to correct misunderstandings and to urge you to reach out to your state board of pharmacy — let them know how your state's action (or inaction) on the FDA's MOU will affect patient access to compounded medications and your business.
If you're a compounder in the Northeast/Mid-Atlantic (Maine to DC) — even if you're not an APC member — please join us for a virtual town hall on compounding issues in 2021.
The Westin on Jekyll Island tells us they've sold out for Saturday night, March 27 (but are holding some rooms for us until February 26). Don't miss out!